Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Golimumab added to conventional DMARDs in biologic-naive rheumatoid arthritis, followed by randomized IV plus SC versus SC maintenance strategies
2009-011137-26Phase 3Completed
- Sponsor
- Merck & Co.
- Start
- Aug 2009
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of golimumab in rheumatoid arthritis (RA) (3 arms), sponsored by Merck & Co. Primary endpoint: Proportion of subjects achieving DAS28-ESR EULAR response. Started Aug 2009; status: completed.
02
Drugs
golimumab
03
Conditions
rheumatoid arthritis (RA)
Beyond the preview
Go deeper on 2009-011137-26.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2009-011137-26.